In this episode (17.47 min), Medicom’s correspondent covers 6 presentations from the 13th International Congress of Dermatology (ICD 2021) which ran continuously from Wednesday 10th to Saturday 13th November 2021.
For ICD 2021, the key themes were Common skin diseases and their treatment, Translational dermatology, Global health and Technology which showcase the opportunities and challenges in the world of dermatology. This was a different set up for a meeting, with 24-hour rolling “dermathon”, with just under 150 hours of presentations, allowing the participant to view content on the virtual platform in your own time zone. This means participants were connected to audiences globally in real-time.
The topics discussed are:
- Common triggers of allergic contact dermatitis in Sri Lanka
Common allergens that trigger allergic contact dermatitis (ACD) can be country-specific. Patients in Sri Lanka underwent patch testing and were found to be most allergic to potassium dichromate, paraphenylenediamine (PPD), and nickel sulphate. - Autologous serum therapy benefits chronic spontaneous urticaria
Autologous serum therapy (AST) is a promising therapy for the treatment of urticaria that does not respond to antihistaminic treatment. The current study showed that it is effective and safe in children. Moreover, it reduces the pill burden and improves the quality of life. - Comparing routes of administration of methotrexate in psoriasis patients
Methotrexate is the most commonly used systematic drug, in both oral and subcutaneous form, in the treatment of psoriasis. A prospective, randomised, single-blinded study found that the efficacy and safety of methotrexate were not associated with the route of administration. - Challenges in diagnosis and treatment of leprosy in Brazil
Leprosy is considered a neglected tropical disease that remains a major public health problem. Brazil is a country with a high leprosy new case detection rate. Key obstacles in Brazil include poor access to diagnosis and late treatment. - Registry of vitiligo patients aims to break the stigma
Vitiligo is a common, acquired, discolouration of the skin. While vitiligo is hardly a disease with a high medical burden, there is a social stigma attached to it because of cosmetic reasons. To raise awareness, in this case in the Russian society, a platform for vitiligo patients has been created to monitor the disease and offer expert advice. - 10% thioglycolic acid gel peels: a safe and efficient option for pigmented purpuric dermatosis
Pigmented purpuric dermatosis (PPD) is a dyspigmentation skin disorder. A treatment option for PPD that has been considered is 10% thioglycolic acid (TGA), which has shown efficacy and safety in a pilot study.
Enjoy listening!
Copyright ©2021 Medicom Medical Publisher
Posted on
Previous Article
« Triplet regimen boosts survival in metastatic melanoma, but at a cost Next Article
Cardiopulmonary exercise test helps define the cause of unexplained dyspnea in COVID long-haulers »
« Triplet regimen boosts survival in metastatic melanoma, but at a cost Next Article
Cardiopulmonary exercise test helps define the cause of unexplained dyspnea in COVID long-haulers »
Table of Contents: ICD 2021
Featured articles
Autologous serum therapy benefits chronic spontaneous urticaria
ICD Round-Up Articles
An unusual case of E. coli cellulitis in an immunocompetent patient
Autologous serum therapy benefits chronic spontaneous urticaria
Comparing routes of administration of methotrexate in psoriasis patients
Expanding the toolbox: what is new in melanoma detection?
Equity in dermatology: Skin Care For All
Challenges in diagnosis and treatment of leprosy in Brazil
A PASSION to provide dermatological care in LMICs
Paediatric dermatology in Tunisia: common diagnoses
Registry of vitiligo patients aims to break the stigma
10% thioglycolic acid gel peels: a safe and efficient option for pigmented purpuric dermatosis
Benefits of microneedling with platelet-rich plasma for acne scars
Related Articles
November 29, 2021
ICD 2021 Highlights Podcast
December 2, 2021
Registry of vitiligo patients aims to break the stigma
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com